Evidence map›Paper›PMID 33932543›Full record

ReviewMicrobial pathogenesis2021

Nanotechnology-based approaches for emerging and re-emerging viruses: Special emphasis on COVID-19.

Muthupandian Saravanan, Ebrahim Mostafavi, Savariar Vincent, Hadush Negash, Rajapriya Andavar, Venkatesan Perumal, Namas Chandra, Selvaraju Narayanasamy, Kalishwaralal Kalimuthu, Hamed Barabadi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Microbial pathogenesis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Photocatalytic TiOMicro and nano engineering · 2022
    Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Muthupandian SaravananDepartment of Medical Microbiology and Immunology, Division of Biomedical Sciences, College of Health Sciences, Mekelle University, P.O.BOX-1871, Mekelle, Ethiopia; Antimicrobial resistance and Nanomedicine Laboratory, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, 600077, India. Electronic address: bioinfosaran@gmail.com.
Ebrahim MostafaviStanford Cardiovascular Institute, Stanford, CA, USA; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Department of Chemical Engineering, Northeastern University, Boston, MA, USA. Electronic address: ebimsv@stanford.edu.
Savariar VincentCentre for Environmental Research and Development (CERD), Loyola Institute of Frontier Energy, Loyola College, Chennai, 600 034, India.
Hadush NegashDepartment of Medical Microbiology, Institute of Biomedical Sciences, College of Medicine and Health Science, Adigrat University, Adigrat, Ethiopia.
Rajapriya AndavarDepartment of Nanoscience and Technology, Bharathiar University, Coimbatore, India.
Venkatesan PerumalCenter for Injury Biomechanics, Materials, and Medicine, Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, NJ,07102, USA.
Namas ChandraCenter for Injury Biomechanics, Materials, and Medicine, Department of Biomedical Engineering, New Jersey Institute of Technology, Newark, NJ,07102, USA.
Selvaraju NarayanasamyDepartment of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam, 781039, India.
Kalishwaralal KalimuthuDepartment of Surgery, School of Medicine, University of Pittsburgh, 5117 Centre Ave, Pittsburgh, PA, 15213, USA.
Hamed BarabadiDepartment of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: barabadi@sbmu.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent decades, the major concern of emerging and re-emerging viral diseases has become an increasingly important area of public health concern, and it is of significance to anticipate future pandemic that would inevitably threaten human lives. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged virus that causes mild to severe pneumonia. Coronavirus disease (COVID-19) became a very much concerned issue worldwide after its super-spread across the globe and emerging viral diseases have not got specific and reliable diagnostic and treatments. As the COVID-19 pandemic brings about a massive life-loss across the globe, there is an unmet need to discover a promising and typically effective diagnosis and treatment to prevent super-spreading and mortality from being decreased or even eliminated. This study was carried out to overview nanotechnology-based diagnostic and treatment approaches for emerging and re-emerging viruses with the current treatment of the disease and shed light on nanotechnology's remarkable potential to provide more effective treatment and prevention to a special focus on recently emerged coronavirus.

Indexed as

COVID-19PandemicsHumansNanotechnologyPublic HealthSARS-CoV-2CoronavirusCOVID-19Inorganic nanoparticlesLipid nanoparticlesNanotherapeuticsPolymeric nanoparticles

Identifiers

PMID33932543
PMCPMC8079947

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.